GlaxoSmithKline will be the most affected, as it represents 26% of the potentially impacted drugs. This is followed by Novartis at 14%, Sanofi at 11%, and both Pfizer and Bayer with 8%.
The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines and determined that the administration of third vaccine doses may increase protection in this population.
The plant technologists and University teachers took part in the development. It will give a deeper understanding of the organic synthesis manufacturing process and...
The collaboration aims to provide Canadians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza...